Long-term outcomes among antiretroviral-naive human immunodeficiency virus-infected patients with small increases in CD4+ cell counts after successful virologic suppression

Clinical Infectious Diseases

Volumn 35, Issue 8, 2002, Pages 1005-1009

  Dronda, Fernando ^a   Moreno, Santiago ^a   Moreno, Ana ^a   Casado, José L ^a   Pérez Elias, María J ^a   Antela, Antonio ^a  

^a HOSPITAL RAMÓN Y CAJAL   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

CD4 ANTIGEN; INDINAVIR; NEVIRAPINE; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; VIRUS RNA;

ADULT; ARTICLE; COHORT ANALYSIS; CONFIDENCE INTERVAL; FEMALE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; LOGISTIC REGRESSION ANALYSIS; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; OUTCOMES RESEARCH; PRIORITY JOURNAL; PROSPECTIVE STUDY;

ADULT; AGED; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4 LYMPHOCYTE COUNT; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; IMMUNITY; MALE; MIDDLE AGED; OUTCOME ASSESSMENT (HEALTH CARE); RISK FACTORS;

EID: 0037108381     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/342695     Document Type: Article

References (22)

1. Sepkowitz KA. Effects of HAART on natural history of AIDS-related opportunistic disorders. Lancet 1998;351:228-30.
2. Mouton Y, Alfandari S, Valette M, et al. Impact of protease inhibitors on AIDS-defining events and hospitalizations in 10 French AIDS reference centres. AIDS 1997; 11:17101-5.
3. Palella FJ, Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N Engl J Med 1998; 338:853-60.
4. Mocroft A, Vella S, Benfield TL, et al. Changing patterns of mortality across Europe in patients infected with HIV-1. Lancet 1998; 352: 1725-30.
5. WHO recommendations for grading of acute and subacute toxicity reporting the results of cancer treatment. Cancer 47; 1981:207-14.
6. Grabar S, Le Moing V, Goujard C, et al. Clinical outcome of patients with HIV-1 infection according to immunologic and virologic response after 6 months of highly active antiretroviral therapy. Ann Intern Med 2000; 133:401-10.
7. Piketty C, Weiss L, Thomas F, Mohamed AS, Belec L, Kazatchkine MD. Long-term clinical outcome of human immunodeficiency virus-infected patients with discordant immunologic and virologic responses to a protease inhibitor-containing regimens. J Infect Dis 2001; 183: 1328-35.
8. Ruiz L, van Lunzen J, Arnó A, et al. Protease inhibitor-containing regimens compared with nucleoside analogues alone in the suppression of persistent HIV-1 replication in lymphoid tissue. AIDS 1999; 13:F1-8.
9. Martínez E, Arnedo M, Giner V, et al. Lymphoid tissue viral burden and duration of viral suppression in plasma. AIDS 2001; 15:1477-82.
10. Kravcik S, Magill A, Sanghvi B, et al. Comparative CD4 T-cell responses of reverse transcriptase inhibitor therapy with or without nelfinavir matched for viral exposure. HIV Clin Trials 2001; 2:160-70.
11. Bartlett JA, DeMasi R, Quinn J, Moxham C, Rousseau F. Overview of the effectiveness of triple combination therapy in antiretroviral-naive HIV-1 infected adults. AIDS 2001; 15:1369-77.
12. + T cell response after virologic failure of protease inhibitor-based regimens in patients with human immunodeficiency virus infection. J Infect Dis 2000; 181:946-53.
13. - T cells in human immunodeficiency virus-infected patients experiencing virologic treatment failure: role of changes in thymic output and T cell death. Centre de Reserche Integré sur le VIH Bichat-Claude Bernard. J Infect Dis 2001; 183:1009-16.
14. Greub B, Lederberger B, Battegay M, et al. Clinical progression, survival and immune recovery during antiretroviral therapy in patients with HIV-1 and hepatitis C virus coinfection: the Swiss HIV Cohort Study. Lancet 2000; 356:1800-5.
15. Martínez E, Gatell J, Morán Y, et al. High incidence of herpes zoster in patients with AIDS soon after therapy with protease inhibitors. Clin Infect Dis 1998; 27:1510-22.
16. Domingo P, Torres OH, Ris J, Vázquez G. Herpes zoster as an immune reconstitution disease after initiation of combination antiretroviral therapy in patients with human immunodeficiency virus type 1 infection. Am J Med 2001; 110:605-9.
17. Davey RT, Murphy RL, Graziano FM, et al. Immunologic and virologic effects of subcutaneous interleukin 2 in combination with antiretroviral therapy. JAMA 2000; 284:183-9.
18. David D, Nait-Inhil L, Dupont B, Maral J, Gachot B, Theze J. Rapid effect of interleukin-2 therapy in human immunodeficiency infected patients whose CD4 cell counts increase only slightly in response to combined antiretroviral treatment. J Infect Dis 2001; 183:730-35.
19. Tambussi G, Ghezzi S, Nozza S, et al. Efficacy of low-dose intermittent subcutaneous interleukin-2 in antiviral drug-experienced human immunodeficiency virus-infected persons with detectable virus load: a controlled study of 3 IL-2 regimens with antiviral drug therapy. J Infect Dis 2001; 183:1476-84.
20. + cell count [abstract 658]. In: Program and abstracts of the 1st International AIDS Society Conference on HIV Pathogenesis and Treatment (Buenos Aires, Argentina). Stockholm, Sweden: International AIDS Society, 2001:276.
21. Lopez Bernaldo de Quiros JC, Miro JM, Pena JM, et al. A randomized trial of the discontinuation of primary and secondary prophylaxis against Pneumocystis carinii pneumonia after highly active antiretroviral therapy in patients with HIV infection. Grupo de Estudio del SIDA 04/98. N Engl J Med 2001; 344:159-67.
22. Lederman MM, Valdez H. immune restoration with antiretroviral therapies: implications for clinical management. JAMA 2000; 284:223-8.